Literature DB >> 19374017

X-ray structure of the ternary MTX.NADPH complex of the anthrax dihydrofolate reductase: a pharmacophore for dual-site inhibitor design.

Brad C Bennett1, Qun Wan, Md Faiz Ahmad, Paul Langan, Chris G Dealwis.   

Abstract

For reasons of bioterrorism and drug resistance, it is imperative to identify and develop new molecular points of intervention against anthrax. Dihydrofolate reductase (DHFR) is a highly conserved enzyme and an established target in a number of species for a variety of chemotherapeutic programs. Recently, the crystal structure of Bacillus anthracis DHFR (baDHFR) in complex with methotrexate (MTX) was determined and, based on the structure, proposals were made for drug design strategies directed against the substrate-binding site. However, little is gleaned about the binding site for NADPH, the cofactor responsible for hydride transfer in the catalytic mechanism. In the present study, X-ray crystallography at 100 K was used to determine the structure of baDHFR in complex with MTX and NADPH. Although the NADPH binding mode is nearly identical to that seen in other DHFR ternary complex structures, the adenine moiety adopts an off-plane tilt of nearly 90 degrees and this orientation is stabilized by hydrogen bonds to functionally conserved Arg residues. A comparison of the binding site, focusing on this region, between baDHFR and the human enzyme is discussed, with an aim at designing species-selective therapeutics. Indeed, the ternary model, refined to 2.3 A resolution, provides an accurate template for testing the feasibility of identifying dual-site inhibitors, compounds that target both the substrate and cofactor-binding site. With the ternary model in hand, using in silico methods, several compounds were identified which could potentially form key bonding contacts in the substrate and cofactor-binding sites. Ultimately, two structurally distinct compounds were verified that inhibit baDHFR at low microM concentrations. The apparent Kd for one of these, (2-(3-(2-(hydroxyimino)-2-(pyridine-4-yl)-6,7-dimethylquinoxalin-2-yl)-1-(pyridine-4-yl)ethanone oxime), was measured by fluorescence spectroscopy to be 5.3 microM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19374017      PMCID: PMC2738603          DOI: 10.1016/j.jsb.2009.01.001

Source DB:  PubMed          Journal:  J Struct Biol        ISSN: 1047-8477            Impact factor:   2.867


  40 in total

1.  Evaluation of PMF scoring in docking weak ligands to the FK506 binding protein.

Authors:  I Muegge; Y C Martin; P J Hajduk; S W Fesik
Journal:  J Med Chem       Date:  1999-07-15       Impact factor: 7.446

2.  Tackling anthrax.

Authors:  A M Friedlander
Journal:  Nature       Date:  2001-11-08       Impact factor: 49.962

3.  Antimicrobial susceptibility of Bacillus anthracis.

Authors:  M Doğanay; N Aydin
Journal:  Scand J Infect Dis       Date:  1991

Review 4.  Perspectives in HIV protease inhibitors.

Authors:  J M Leonard
Journal:  Adv Exp Med Biol       Date:  1996       Impact factor: 2.622

5.  In search of dihydrofolate reductase.

Authors:  F M Huennekens
Journal:  Protein Sci       Date:  1996-06       Impact factor: 6.725

6.  Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes.

Authors:  M D Eldridge; C W Murray; T R Auton; G V Paolini; R P Mee
Journal:  J Comput Aided Mol Des       Date:  1997-09       Impact factor: 3.686

7.  Plasmodium falciparum: kinetic interactions of WR99210 with pyrimethamine-sensitive and pyrimethamine-resistant dihydrofolate reductase.

Authors:  M Hekmat-Nejad; P K Rathod
Journal:  Exp Parasitol       Date:  1997-11       Impact factor: 2.011

8.  Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation.

Authors:  G Jones; P Willett; R C Glen
Journal:  J Mol Biol       Date:  1995-01-06       Impact factor: 5.469

9.  In vitro efficacy of new antifolates against trimethoprim-resistant Bacillus anthracis.

Authors:  Esther W Barrow; Jürg Dreier; Stefan Reinelt; Philip C Bourne; William W Barrow
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

10.  Crystal structure of the anthrax drug target, Bacillus anthracis dihydrofolate reductase.

Authors:  Brad C Bennett; Hai Xu; Richard F Simmerman; Richard E Lee; Chris G Dealwis
Journal:  J Med Chem       Date:  2007-08-14       Impact factor: 7.446

View more
  10 in total

1.  Charged Nonclassical Antifolates with Activity Against Gram-Positive and Gram-Negative Pathogens.

Authors:  Eric Scocchera; Stephanie M Reeve; Santosh Keshipeddy; Michael N Lombardo; Behnoush Hajian; Adrienne E Sochia; Jeremy B Alverson; Nigel D Priestley; Amy C Anderson; Dennis L Wright
Journal:  ACS Med Chem Lett       Date:  2016-05-05       Impact factor: 4.345

2.  Classification of ligand molecules in PDB with graph match-based structural superposition.

Authors:  Clara Shionyu-Mitsuyama; Atsushi Hijikata; Toshiyuki Tsuji; Tsuyoshi Shirai
Journal:  J Struct Funct Genomics       Date:  2016-12-23

Review 3.  New developments in vaccines, inhibitors of anthrax toxins, and antibiotic therapeutics for Bacillus anthracis.

Authors:  J M Beierlein; A C Anderson
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

4.  Modified 2,4-diaminopyrimidine-based dihydrofolate reductase inhibitors as potential drug scaffolds against Bacillus anthracis.

Authors:  Baskar Nammalwar; Christina R Bourne; Nancy Wakeham; Philip C Bourne; Esther W Barrow; N Prasad Muddala; Richard A Bunce; K Darrell Berlin; William W Barrow
Journal:  Bioorg Med Chem       Date:  2014-11-11       Impact factor: 3.641

Review 5.  Advances in Applying Computer-Aided Drug Design for Neurodegenerative Diseases.

Authors:  Mootaz M Salman; Zaid Al-Obaidi; Philip Kitchen; Andrea Loreto; Roslyn M Bill; Richard Wade-Martins
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

6.  Histidine hydrogen-deuterium exchange mass spectrometry for probing the microenvironment of histidine residues in dihydrofolate reductase.

Authors:  Masaru Miyagi; Qun Wan; Md Faiz Ahmad; Giridharan Gokulrangan; Sara E Tomechko; Brad Bennett; Chris Dealwis
Journal:  PLoS One       Date:  2011-02-16       Impact factor: 3.240

7.  Hypothesis-Driven, Structure-Based Design in Photopharmacology: The Case of eDHFR Inhibitors.

Authors:  Piermichele Kobauri; Nicole S Galenkamp; Albert M Schulte; Jisk de Vries; Nadja A Simeth; Giovanni Maglia; Sebastian Thallmair; Dušan Kolarski; Wiktor Szymanski; Ben L Feringa
Journal:  J Med Chem       Date:  2022-03-08       Impact factor: 7.446

8.  An innovative strategy for dual inhibitor design and its application in dual inhibition of human thymidylate synthase and dihydrofolate reductase enzymes.

Authors:  Mahreen Arooj; Sugunadevi Sakkiah; Guang ping Cao; Keun Woo Lee
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

Review 9.  Utility of the Biosynthetic Folate Pathway for Targets in Antimicrobial Discovery.

Authors:  Christina R Bourne
Journal:  Antibiotics (Basel)       Date:  2014-01-21

10.  Design, synthesis, and biological evaluation of novel N 4 -substituted sulfonamides: acetamides derivatives as dihydrofolate reductase (DHFR) inhibitors.

Authors:  Essam M Hussein; Munirah M Al-Rooqi; Shimaa M Abd El-Galil; Saleh A Ahmed
Journal:  BMC Chem       Date:  2019-07-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.